Skip to main content

Advertisement

Fig. 6 | Molecular Cancer

Fig. 6

From: CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

Fig. 6

a. Proteins were extracted from isolated tumor of each group. Proteome profiler human phosphokinase array was performed. The table represents the fold increase of pixel density of each condition compared to control. b. Western blot for phospho-PYK2 and total-PYK2 was performed on OCCs (APOCC and APOCC SH-IL6) co-incubated or not with MSC for 48 h and treated or not with chemotherapy Carboplatin (100 μM) and Taxol (0.1 μM) for 24 h. c. Western blot for phospho-PYK2 and total-PYK2 was performed on OCCs (APOCC) co-incubated or not with MSC in presence or not of PF431396 (5 μM) for 48 h and treated or not with chemotherapy Carboplatin (100 μM) and Taxol (0.1 μM) for 24 h. d. The relative quantification of IL-6 (gene was performed by RT-PCR. The histogram represents ratios between each condition and the control group (no MSC, no chemotherapy) of their 2–ΔΔCp real-time PCR values. e. OCCs (Ovcar3, APOCC and Skov3) were co-incubated or not with MSC in presence or not of PF431396 (5 μM) for 48 h. Supernatants were harvested and an Elisa assay for IL-6 was performed on the supernatant of the cells. Histograms represent the mean (±SEM) for triplicates. f. Western blot for phospho-PYK2 and total PYK2 was performed on OCCs (Ovcar3, APOCC and Skov3) incubated with IL-6 (50 ng/ml) for 6 h. g. OCCs (Ovcar3, APOCC and Skov3) were treated with MCP-1 (10 nM), CCL5 (100 ng/ml), IL-6 (50 ng/ml) or co-incubated with MSC, in presence (light graph) or not (plain graph) of PF431396 (5 μM) for 48 h prior treatment with Carboplatin (100 μM) and Taxol (0.1 μM) for 24 h. Histograms represent the ratio of living cells compared to the not treated cells. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)

Back to article page